BUFFALO, N.Y. — Buffalo-based MimiVax has raised millions as it works toward commercialization of its cancer immunotherapy drug.
The spin-off from Roswell Park Comprehensive Cancer Center recently raised a nearly $5.8 million convertible debt round to continue its phase 2B clinical trial for SurVaxM, its cancer immunotherapy drug. The round is expected to close by the end of August, according to CEO and co-founder Dr. Michael Ciesielski.
“Our drug and our company really spawned off of a Buffalo community effort,” he said. “We started with a funds donation from Roswell Park and … the Buffalo community.”
The trial, which started recruiting in Q1 2022, is for newly diagnosed glioblastoma patients. Glioblastoma is a fast-growing tumor that forms in the brain or spinal cord.
Read more from our partners at Buffalo Business First.
Related Video:
